| scholarly article | Q13442814 |
| P50 | author | Irina Caminschi | Q41610434 |
| P2093 | author name string | Kristen J Radford | |
| P2860 | cites work | Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin | Q24315864 |
| CLEC9A is a novel activation C-type lectin-like receptor expressed on BDCA3+ dendritic cells and a subset of monocytes | Q24320164 | ||
| Batf3 Deficiency Reveals a Critical Role for CD8 + Dendritic Cells in Cytotoxic T Cell Immunity | Q27489852 | ||
| The dendritic cell receptor Clec9A binds damaged cells via exposed actin filaments | Q27678371 | ||
| Compensatory dendritic cell development mediated by BATF-IRF interactions | Q28586184 | ||
| Peripheral CD103+ dendritic cells form a unified subset developmentally related to CD8alpha+ conventional dendritic cells | Q28591976 | ||
| Differential antigen processing by dendritic cell subsets in vivo | Q29615177 | ||
| IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors | Q29618425 | ||
| Batf3-dependent CD11b(low/-) peripheral dendritic cells are GM-CSF-independent and are not required for Th cell priming after subcutaneous immunization | Q31040402 | ||
| Nectin-like protein 2 defines a subset of T-cell zone dendritic cells and is a ligand for class-I-restricted T-cell-associated molecule | Q31154958 | ||
| The origin and development of nonlymphoid tissue CD103+ DCs. | Q33590397 | ||
| CD207+ CD103+ dermal dendritic cells cross-present keratinocyte-derived antigens irrespective of the presence of Langerhans cells | Q33615124 | ||
| Toll-like receptors activate innate and adaptive immunity by using dendritic cell-intrinsic and -extrinsic mechanisms | Q33762668 | ||
| Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. | Q33902330 | ||
| The XC chemokine receptor 1 is a conserved selective marker of mammalian cells homologous to mouse CD8alpha+ dendritic cells | Q33902379 | ||
| Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8alpha+ dendritic cells | Q33902421 | ||
| CD8(+) but not CD8(-) dendritic cells cross-prime cytotoxic T cells in vivo. | Q33928441 | ||
| Comparable T helper 1 (Th1) and CD8 T-cell immunity by targeting HIV gag p24 to CD8 dendritic cells within antibodies to Langerin, DEC205, and Clec9A. | Q34573130 | ||
| Steady-state and inflammatory dendritic-cell development | Q34591334 | ||
| Efficient and versatile manipulation of the peripheral CD4+ T-cell compartment by antigen targeting to DNGR-1/CLEC9A. | Q34725185 | ||
| Protective T cell immunity in mice following protein-TLR7/8 agonist-conjugate immunization requires aggregation, type I IFN, and multiple DC subsets. | Q34875973 | ||
| Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates. | Q34880294 | ||
| CD8α(+) dendritic cells are the critical source of interleukin-12 that controls acute infection by Toxoplasma gondii tachyzoites | Q35209897 | ||
| Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humans | Q35669097 | ||
| Dendritic cell-targeted protein vaccines: a novel approach to induce T-cell immunity | Q35680858 | ||
| Targeting Dendritic Cells in vivo for Cancer Therapy | Q35928270 | ||
| Expression of XCR1 Characterizes the Batf3-Dependent Lineage of Dendritic Cells Capable of Antigen Cross-Presentation | Q36101313 | ||
| Human tissues contain CD141hi cross-presenting dendritic cells with functional homology to mouse CD103+ nonlymphoid dendritic cells | Q36333494 | ||
| Vaginal submucosal dendritic cells, but not Langerhans cells, induce protective Th1 responses to herpes simplex virus-2 | Q36370493 | ||
| Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance | Q36376611 | ||
| In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination | Q36402359 | ||
| The efficacy of DNA vaccination is enhanced in mice by targeting the encoded protein to dendritic cells | Q36489528 | ||
| Novel insights into the relationships between dendritic cell subsets in human and mouse revealed by genome-wide expression profiling | Q36673501 | ||
| The dendritic cell subtype-restricted C-type lectin Clec9A is a target for vaccine enhancement | Q36941087 | ||
| Dendritic cell vaccines in melanoma: from promise to proof? | Q37080512 | ||
| Identification of a dendritic cell receptor that couples sensing of necrosis to immunity | Q37164859 | ||
| Intradermal vaccine delivery: will new delivery systems transform vaccine administration? | Q37166403 | ||
| Dendritic cell subsets in primary and secondary T cell responses at body surfaces | Q37633373 | ||
| What role does the route of immunization play in the generation of protective immunity against mucosal pathogens? | Q37634790 | ||
| The CD8+ dendritic cell subset | Q37700814 | ||
| The secret ally: immunostimulation by anticancer drugs | Q37981038 | ||
| The Role of XCR1 and its Ligand XCL1 in Antigen Cross-Presentation by Murine and Human Dendritic Cells | Q38008352 | ||
| The conduit system transports soluble antigens from the afferent lymph to resident dendritic cells in the T cell area of the lymph node | Q38459394 | ||
| DNGR-1 is a specific and universal marker of mouse and human Batf3-dependent dendritic cells in lymphoid and nonlymphoid tissues | Q39374974 | ||
| Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice | Q39827951 | ||
| Superior antigen cross-presentation and XCR1 expression define human CD11c+CD141+ cells as homologues of mouse CD8+ dendritic cells | Q40952120 | ||
| Route of antigen uptake differentially impacts presentation by dendritic cells and activated monocytes | Q41578289 | ||
| Mouse CD8alpha+ DCs and human BDCA3+ DCs are major producers of IFN-lambda in response to poly IC. | Q41676655 | ||
| Cross-presentation of viral and self antigens by skin-derived CD103+ dendritic cells | Q43647446 | ||
| Cutting edge: Clec9A+ dendritic cells mediate the development of experimental cerebral malaria | Q43729235 | ||
| Human CD1c (BDCA-1)+ myeloid dendritic cells secrete IL-10 and display an immuno-regulatory phenotype and function in response to Escherichia coli. | Q45186970 | ||
| Spatial and mechanistic separation of cross-presentation and endogenous antigen presentation | Q46674193 | ||
| Selection of an antibody library identifies a pathway to induce immunity by targeting CD36 on steady-state CD8 alpha+ dendritic cells. | Q47896838 | ||
| Toll-like receptor expression in murine DC subsets: lack of TLR7 expression by CD8 alpha+ DC correlates with unresponsiveness to imidazoquinolines. | Q47997828 | ||
| Cutting edge: expression of XCR1 defines mouse lymphoid-tissue resident and migratory dendritic cells of the CD8α+ type. | Q51852802 | ||
| Human Dendritic Cell Subsets from Spleen and Blood Are Similar in Phenotype and Function but Modified by Donor Health Status | Q51869621 | ||
| Selective expression of the chemokine receptor XCR1 on cross-presenting dendritic cells determines cooperation with CD8+ T cells | Q52907264 | ||
| Targeting antigen to mouse dendritic cells via Clec9A induces potent CD4 T cell responses biased toward a follicular helper phenotype | Q53085484 | ||
| F-Actin Is an Evolutionarily Conserved Damage-Associated Molecular Pattern Recognized by DNGR-1, a Receptor for Dead Cells | Q56880701 | ||
| Inflammatory mediators are insufficient for full dendritic cell activation and promote expansion of CD4+ T cell populations lacking helper function | Q56880717 | ||
| Mouse type I IFN-producing cells are immature APCs with plasmacytoid morphology | Q56987531 | ||
| Antibody responses initiated by Clec9A-bearing dendritic cells in normal and Batf3−/− mice | Q57133229 | ||
| The C-Type Lectin Clec12A Present on Mouse and Human Dendritic Cells Can Serve as a Target for Antigen Delivery and Enhancement of Antibody Responses | Q57133306 | ||
| Normal proportion and expression of maturation markers in migratory dendritic cells in the absence of germs or Toll-like receptor signaling | Q57227671 | ||
| Migratory Dendritic Cells Transfer Antigen to a Lymph Node-Resident Dendritic Cell Population for Efficient CTL Priming | Q57227729 | ||
| Cutting Edge: Intravenous Soluble Antigen Is Presented to CD4 T Cells by CD8- Dendritic Cells, but Cross-Presented to CD8 T Cells by CD8+ Dendritic Cells | Q57227937 | ||
| Toll-dependent selection of microbial antigens for presentation by dendritic cells | Q59063722 | ||
| Differential production of IL-12, IFN-alpha, and IFN-gamma by mouse dendritic cell subsets | Q73785333 | ||
| Differential development of murine dendritic cells by GM-CSF versus Flt3 ligand has implications for inflammation and trafficking | Q79912711 | ||
| Dendritic cells in cancer immunotherapy | Q79967042 | ||
| Preferential induction of CD4+ T cell responses through in vivo targeting of antigen to dendritic cell-associated C-type lectin-1 | Q80057988 | ||
| Antigenic targeting of the human mannose receptor induces tumor immunity | Q80257353 | ||
| P433 | issue | 2 | |
| P921 | main subject | dendritic cell | Q506253 |
| P304 | page(s) | 259-264 | |
| P577 | publication date | 2013-01-04 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Human Vaccines & Immunotherapeutics | Q21072749 |
| P1476 | title | New generation of dendritic cell vaccines | |
| P478 | volume | 9 |
| Q92815242 | A DNA-Modified Live Vaccine Prime-Boost Strategy Broadens the T-Cell Response and Enhances the Antibody Response against the Porcine Reproductive and Respiratory Syndrome Virus |
| Q98513637 | A vaccine combination of lipid nanoparticles and a cholera toxin adjuvant derivative greatly improves lung protection against influenza virus infection |
| Q38288055 | Cancer immunotherapy: nanodelivery approaches for immune cell targeting and tracking |
| Q39140492 | Co-operative suppression of inflammatory responses in human dendritic cells by plant proanthocyanidins and products from the parasitic nematode Trichuris suis |
| Q34657557 | Dendritic cells in progression and pathology of HIV infection. |
| Q38114071 | Dendritic cells: cellular mediators for immunological tolerance |
| Q28087687 | Dendritic-cell-based technology landscape: Insights from patents and citation networks |
| Q47547305 | Glycan recognition by human blood mononuclear cells with an emphasis on dendritic cells |
| Q33659782 | Harnessing Human Cross-Presenting CLEC9A(+)XCR1(+) Dendritic Cells for Immunotherapy |
| Q33998442 | Human XCR1+ dendritic cells derived in vitro from CD34+ progenitors closely resemble blood dendritic cells, including their adjuvant responsiveness, contrary to monocyte-derived dendritic cells |
| Q33906222 | Modifying Dendritic Cell Activation with Plasmonic Nano Vectors |
| Q37277188 | Targeting CLEC9A delivers antigen to human CD141(+) DC for CD4(+) and CD8(+)T cell recognition |
| Q38235001 | Targeting human dendritic cells in situ to improve vaccines. |
| Q40728648 | Therapeutic Cancer Vaccines |
| Q52848957 | Vaccination with trifunctional nanoparticles that address CD8+ dendritic cells inhibits growth of established melanoma |
Search more.